ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2018
Clinical analysis of 90 cases of malignant lacrimal sac tumor.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Primary Malignant Melanoma of the Nasolacrimal Duct Presenting Without Hemolacria: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2026Article
- Article
- Primary adenocarcinoma of the lacrimal sac with 5-year recurrence-free survival after radiation therapy alone: a case report.International cancer conference journal · 2025Article
- Nasolacrimal Metastasis from Parotid Ductal Carcinoma Detected byMolecular imaging and radionuclide therapy · 2025Article
- Exclusive or combined endoscopic approach to tumours of the lower lacrimal pathway: review of the literature.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024Review
- Lacrimal sac squamous cell carcinoma: From resection to prosthetic rehabilitation. A case report.Clinical case reports · 2023Article
- Timing of Jones Tube Placement After Excision of Nasal or Lacrimal Drainage System Malignancy: A Survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS).Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Investigation of lacrimal sac space-occupying lesions using color doppler ultrasound, computed tomography, and computed tomography dacryocystography.International journal of ophthalmology · 2023Article
- Timing and Indications of Jones Tube Placement in Lacrimal Drainage System Malignancy Patients: A Rebuttal to the Letter by Shah et al [Response to Letter].Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Epiphora in Treated Lacrimal Drainage System Malignancy Patients - When and Whom to Treat? [Letter].Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Lacrimal sac lymphoma: a case series and literature review.International journal of ophthalmology · 2022Article
- Treatment outcomes after definitive radio(chemo)therapy for 17 lacrimal sac squamous cell carcinoma.The British journal of radiology · 2020Review
- Complete resolution of a large squamous cell carcinoma of the lacrimal duct in a young African American male after non-surgical management.American journal of ophthalmology case reports · 2020Article
- Immunoglobulin G4-related lacrimal sac dacryocystocele: A novel case report.American journal of ophthalmology case reports · 2020Article
- CT and MRI findings in relapsing primary malignant melanoma of the lacrimal sac: a case report and brief literature review.BMC ophthalmology · 2020Review
- [Masquerade lacrimal duct stenosis: prevalence of lacrimal sac tumors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Article
- Comparison of Clinical Features and Treatment Outcome in Benign and Malignant Lacrimal Sac Tumors.BioMed research international · 2020Article
- Lacrimal sac tumors: A case series over 27 years.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- HER2-Positive Lacrimal Sac Squamous Cell Carcinoma in a 57-Year-Old Man.Case reports in oncologyArticle
- Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the pathology, clinical manifestations, and potential risk factors associated with the prognosis of malignant lacrimal sac tumors. In addition, the treatment outcomes and complications were also evaluated.
methodsNinety cases of malignant lacrimal sac tumors were retrospectively analyzed at our hospital. Pathological classifications, clinical manifestations, risk factors, and follow-up time were documented. The outcomes and complications were evaluated and compared among the various treatment modalities.
resultsThe median follow-up time was 50 months (range, 3-258 months). The 5-year overall survival (OS) and progression-free survival (PFS) for all cases were 85.7 and 77.9%, respectively. The 5-year OS and PFS for 69 cases of squamous cell carcinoma were 87.6 and 76.3%, and which were 80.4 and 72.4% for 21 cases of non-squamous cell carcinoma, respectively. There was no difference of 5-year OS and PFS between squamous cell carcinoma and non-squamous cell carcinoma (p = 0.350 and p = 0.946). Positive lymph node status was associated with worse OS (p < 0.001) and PFS (p = 0.020). For the 23.3% of cases (21/90) treated with the definitive radiotherapy, the outcomes were equivalent to that of surgery combined with radiotherapy, with the incidence of treatment-related visual acuity complication not being significant. The addition of chemotherapy to the treatment course had a marginal and non-significant improvement in OS and distant metastasis-free survival.
conclusionsLymph node status was found to be a key factor for prognosis. Advanced tumors could benefit from multimodality treatment, with radiotherapy playing an important role. However, the role of chemotherapy requires further investigation.
Indexed as
Identifiers
29707735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.